Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Bls 1 frá 46 niðurstöður
Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
This retrospective study was undertaken to obtain information regarding the survival and toxicities after Yttrium-90 microspheres treatment in patients with primary liver malignancies. Baseline, treatment, and follow-up data were collected and analyzed for 21 patients treated with Yttrium-90
Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
The aim of this study was to assess the effectiveness of yttrium-90 (90 Y) microspheres for the treatment of unresectable metastatic liver neuroendocrine tumors (NET).
METHODS
From February 2006 to September 2015, 36 patients (19 male and 17 female, age 63.6 ± 9.4 years) who underwent 90 Y
Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND
: The objective of the current study was to determine the safety and efficacy of Yttrium-90 (Y90) microsphere treatment in patients with liver-dominant colorectal metastases.
METHODS
: Seventy-two patients with unresectable hepatic colorectal metastases were treated at a targeted absorbed
A systematic review of yttrium-90 radioembolization for unresectable liver metastases of melanoma.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
To assess the effectiveness of yttrium-90 (90Y) radioembolization in the treatment of unresectable liver metastases of melanoma.
METHODS
PubMed and EMBASE were systemically searched for all English language studies related to 90Y radioembolization for unresectable liver metastases of
Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The aim of the study was to analyze the safety and efficacy of yttrium-90 ((90)Y) radioembolization in the treatment of unresectable hepatic melanoma metastases refractory to previous systemic/locoregional therapy. Between February 2004 and April 2010, 16 patients with hepatic melanoma metastases
Transarterial radioembolization with Yttrium-90 for regional management of hepatocellular cancer: the early results of a nontransplant center.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Selective arterial radioembolization with Yttrium-90 (Y-90) microspheres has shown promise for regional management of hepatocellular cancer (HCC). Our objective was to report our early experience with this treatment modality from a nontransplant center. Treatment of patients with HCC was discussed
Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: results from a pilot study.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
To evaluate the safety and efficacy of yttrium-90 ((90)Y) radioembolization with extended-shelf-life glass microspheres. We postulated that this approach, for the same planned tissue dose of 120 Gy, would increase the embolic load, improve distribution, and result in enhanced tumor
A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
Over the past two decades, several advances have been made in the management of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). Yttrium-90 ( 90 Y) radioembolization has recently been made a treatment option for patients with HCC and PVTT. However,
Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
To evaluate outcomes of yttrium-90 radioembolization performed with glass-based microspheres in the treatment of hepatocellular carcinoma (HCC) secondary to the hepatitis B virus (HBV).
METHODS
A total of 675 patients treated between January 2006 and July 2014 were reviewed, of which 45
Yttrium 90 microspheres for the treatment of hepatocellular carcinoma.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Yttrium-90 microspheres are radioactive particles which are increasingly being employed for treating patients with unresectable hepatocellular carcinoma (HCC). The procedure is called radioembolization. It involves the injection of micron-sized embolic particles loaded with a radioisotope by use of
Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
Patients with portal vein thrombosis (PVT) and hepatocellular carcinoma (HCC) have limited treatment options because of increased disease burden and diminished hepatic perfusion. Yttrium-90 ((90)Y) microspheres may be better tolerated than chemoembolization in these patients. The present
Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
Hepatocellular carcinoma (HCC) is the sixth most common cancer and third leading cause of cancer-related death in the world. The management of unresectable HCC and hepatic metastases from various solid tumors is a clinical dilemma. There is paucity of data on the treatment of unresectable
Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Yttrium-90 (Y-90) radioembolization is an emerging treatment option for unresectable neuroendocrine liver metastases (NELM). However, the data regarding this treatment are currently limited. This study evaluates the efficacy and tolerability of Y-90 radioembolization and identifies prognostic
Impact of prior hepatectomy on the safety and efficacy of radioembolization with yttrium-90 microspheres for patients with unresectable liver tumors.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
Yttrium-90 (Y) radioembolization is increasingly used as a minimally invasive therapy for unresectable liver tumors; however, previous hepatectomy must be considered to avoid excessive hepatic insult. A retrospective analysis was undertaken to investigate the viability of performing
Gastric radiation enteritis after intra-arterial yttrium-90 microsphere therapy for early stage hepatocellular carcinoma.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
As clinicians who treat hepatocellular carcinoma move yttrium-90 intra-arterial radiotherapy from the palliative setting to the treatment of patients with potentially curable early stage disease, more intense scrutiny of the safety of that procedure is warranted. To demonstrate the
Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum
- Virkar á 55 tungumálum
- Jurtalækningar studdir af vísindum
- Jurtaviðurkenning eftir ímynd
- Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
- Lestu vísindarit sem tengjast leit þinni
- Leitaðu að lækningajurtum eftir áhrifum þeirra
- Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum
Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum
